key: cord-0945559-zxrv9aha
authors: Ahava, M. J.; Jarva, H.; Jääskeläinen, A. J.; Lappalainen, M. J.; Vapalahti, O.; Kurkela, S.
title: Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland
date: 2022-03-30
journal: nan
DOI: 10.1101/2022.03.25.22272952
sha: 23134cf6c09110f26b84580a727638f9b0c98f04
doc_id: 945559
cord_uid: zxrv9aha

Objectives The aim of this study was to assess changes in exposure and prevalence of SARS-CoV-2 infection during the first months of emergence of Omicron variant in the Greater Helsinki area, Finland. Methods A prospective seroepidemiological survey of SARS-CoV-2 was conducted on 1,600 serum specimens sent to Helsinki University Hospital Laboratory (HUSLAB) for HIV serology between 15 November 2021 and 6 March 2022 (calendar weeks 46/2021 - 9/2022). For each calendar week, 100 serum specimens were randomly selected and analysed for SARS-CoV-2 IgG antibodies against nucleocapsid (N) and spike 1 (S1) protein with Abbott SARS-CoV-2 IgG (N protein) and SARS-CoV-2 IgG II Quant (S protein) tests, respectively. Results The prevalence of N antibodies increased from 5.2% (weeks 46-50/2021) to 28.2% (weeks 5-9/2022) during the study period. The proportion of seronegative samples as well as anti-N negative, anti-S1 positive samples decreased correspondingly from 11.6% to 3.8%, and 84.2% to 68.2%, respectively. Anti-N positive samples that were anti-S1 negative only began to appear as of week 2/2022. Conclusions A rapid increase in the N antibody prevalence was observed over the study period, suggesting a high transmission rate. A substantial proportion of COVID-19 cases remained undiagnosed during the emergence of Omicron variant in the Greater Helsinki Area, Finland.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

We would like to thank Ms. Irina Leino and Ms. Merja Heikkinen (Department of Virology and 23 Immunology, HUSLAB) for excellent technical assistance. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Abstract 26 Objectives 27

The aim of this study was to assess changes in exposure and prevalence of SARS-CoV-2 infection 28 during the first months of emergence of Omicron variant in the Greater Helsinki area, Finland.

A prospective seroepidemiological survey of SARS-CoV-2 was conducted on 1,600 serum 31 specimens sent to Helsinki University Hospital Laboratory (HUSLAB) for HIV serology between 32 15 November 2021 and 6 March 2022 (calendar weeks 46/2021 -9/2022). For each calendar week, 33 100 serum specimens were randomly selected and analysed for SARS-CoV-2 IgG antibodies 34 against nucleocapsid (N) and spike 1 (S1) protein with Abbott SARS-CoV-2 IgG (N protein) and 35 SARS-CoV-2 IgG II Quant (S protein) tests, respectively.

The prevalence of N antibodies increased from 5.2% (weeks 46-50/2021) to 28.2% (weeks 5-38 9/2022) during the study period. The proportion of seronegative samples as well as anti-N negative, 39 anti-S1 positive samples decreased correspondingly from 11.6% to 3.8%, and 84.2% to 68.2%, 40 respectively. Anti-N positive samples that were anti-S1 negative only began to appear as of week 41 2/2022.

A rapid increase in the N antibody prevalence was observed over the study period, suggesting a is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 The emergence of SARS-CoV-2 Omicron variant (B.1.1.529) as of November 2021 changed the 48 epidemiology of COVID-19 with rapid upsurge of cases globally [1, 2] . In Finland, the first patient 49 case with Omicron variant was detected on 29 November 2021 [3] . In this study, we conducted a 

If the analysis failed or the specimen volume was not adequate, the sample was replaced by one of 64 the spare samples of that calendar week.

The subgroups identified according to serostatus were I) anti-N negative, anti-S1 negative: no 66 serological evidence of vaccine immunization or previous infection; II) anti-N negative, anti-S1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The study subjects' age ranged from 11 months to 94 years (median 33 years; IQR 26-46 years), 74 and the proportion of women was 55.2%. The baseline prevalence of N antibodies in the first five 75 weeks of the study period (46-50/2021) was 5.2%, while in the final five weeks (5-9/2022) it was 76 28.2%. The proportion of seronegative samples for the corresponding time frames was 11.6% and 77 3.8%, and for anti-N negative, anti-S1 positive samples 84.2% and 68.2%. Figure 1 depicts the 78 moving average of the N antibody seroprevalence over the study period: the sharpest increase was 79 observed in those aged <30 years. In late 2021, the seroprevalence of N antibodies was consistently 80 well below 10% but began a rapid incline as of week 1/2022 and surpassed 20% on week 3/2022.

Anti-N positive samples that were anti-S1 negative began to appear on week 2/2022 and By mid-December 2021, Omicron had become the primary variant in the Greater Helsinki area [3] .

Soon after, our data show a rapid increase in the population level exposure to SARS-CoV-2. This 89 indicates a high transmission rate and is in line with previous reports from elsewhere [4, 5, 6] . At the 90 end of the study period (week 9/2022), 4% were seronegative in N and S antibody testing.

Altogether 78% (1241/1600) had S antibodies without N antibodies, suggesting vaccine 92 immunization without recent COVID-19 infection.

Our study design did not allow differentiation between those who had undergone COVID-19 with 94 or without prior vaccine immunization. Also, protective immunity against SARS-CoV-2 cannot be 95 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101/2022.03.25.22272952 doi: medRxiv preprint determined by detection of antibodies to N or S antigen by enzyme immunoassays. As the purpose 96 of this study was to provide real-time data, conducting neutralization assays was not feasible.

The present study showed a rapid increase in the N antibody prevalence, indicating that 98 approximately 23% (comparing the first and last five weeks of the study period) of the tested is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Conflict of interest: None of the authors have conflict of interest. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Assessment of the further emergence and potential impact of the SARS-125

CoV-2 Omicron variant of concern in the context of ongoing transmission of the 126

Delta variant of concern in the EU/EEA, 18th update

COVID-19) Dashboard

Introduction and rapid spread of SARS-130

CoV-2 Omicron variant and the dynamics of its sub-lineages BA.1 and BA

PREPRINT (Version 1) available at 132 Research Square

SARS-CoV-2 B.1.1.529 (Omicron)

Variant Transmission Within Households -Four U.S. Jurisdictions

Outbreak caused by the SARS-CoV-2

Serial Intervals and Household Transmission of 141